Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer(SURGIGAST) | terminated | Phase 3 | 6 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06420349 | NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | terminated | Phase 1 | 7 | Mayo ClinicOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05044676 | Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma(IMMUNOCELL) | terminated | — | 4 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | terminated | Phase 2 / Phase 3 | 18 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05998447 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | terminated | Phase 2 | 10 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT01023412 | Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery(IPOD-3) | terminated | N/A | 107 | Société des Produits Nestlé (SPN)INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | terminated | Phase 2 | 4 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06199466 | A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05114213 | MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC(MASPAC) | terminated | Phase 2 | 9 | Ludwig-Maximilians - University of MunichOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05427396 | A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT06320080 | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. | terminated | Phase 1 | 22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02885142 | Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery?(MUCEM) | terminated | N/A | 368 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | terminated | Phase 1 | 4 | Colin D. Weekes, M.D., PhDOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04844970 | Anamorelin Study for Advanced Pancreatic Cancer | terminated | Phase 2 | 4 | Lahey ClinicOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)(OXTEND-01) | terminated | Phase 1 | 19 | Debiopharm International SAINDUSTRY | 8 | Nov 17, 2025 | clinicaltrials |
| NCT05525286 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma(CLAUDIO-01) | terminated | Phase 1 / Phase 2 | 31 | SOTIO Biotech a.s.INDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | terminated | Phase 1 | 17 | Bolt Biotherapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05980416 | Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | terminated | Phase 1 | 88 | Elevation OncologyINDUSTRY | 3 | Nov 14, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05246839 | Informed Choice - Compass | terminated | — | 1,823 | Exact Sciences CorporationINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 82 | Nuvation Bio Inc.INDUSTRY | 2 | Nov 6, 2025 | clinicaltrials |
| NCT06069778 | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 1 | BioNTech SEINDUSTRY | 1 | Oct 31, 2025 | clinicaltrials |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery | terminated | N/A | 41 | University of WashingtonOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | terminated | Phase 1 / Phase 2 | 23 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | HiFiBiO TherapeuticsINDUSTRY | 2 | Oct 22, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT00422877 | Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract | terminated | Phase 2 | 13 | American Regent, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | terminated | Phase 2 | 13 | NYU Langone HealthOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT06275854 | YASU Research Registry: For Young Adults With Cancer | terminated | — | 192 | Young Adult Survivors UnitedOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer(DisTinGuish) | terminated | Phase 2 | 247 | Leap Therapeutics, Inc.INDUSTRY | 3 | Oct 9, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT02982694 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | terminated | Phase 2 | 46 | Vall d'Hebron Institute of OncologyOTHER | 4 | Oct 1, 2025 | clinicaltrials |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 9 | Sep 30, 2025 | clinicaltrials |
| NCT04827732 | Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer(IMPARC) | terminated | N/A | 15 | Washington University School of MedicineOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05350501 | EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer(CLAUDE) | terminated | Phase 2 | 1 | EnteromeINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05221320 | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | terminated | Phase 2 | 47 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06302400 | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma(RHEPaiR) | terminated | N/A | 4 | Imperial College LondonOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04938973 | NIF-Guided RAMIE Using ICG Versus OTE Feasibility RCT(RAMIE vs OTE) | terminated | N/A | 24 | St. Joseph's Healthcare HamiltonOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | terminated | Phase 1 | 9 | PfizerINDUSTRY | 3 | Sep 17, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT05013554 | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors | terminated | Phase 1 | 44 | SanofiINDUSTRY | 6 | Sep 15, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Dec 23, 2025source: clinicaltrials